Spots Global Cancer Trial Database for dinutuximab
Every month we try and update this database with for dinutuximab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma | NCT02484443 | Metastatic Mali... Metastatic Oste... Recurrent Osteo... | Dinutuximab Laboratory Biom... Pharmacological... Sargramostim | - 29 Years | National Cancer Institute (NCI) | |
| A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma | NCT04238819 | Relapsed Solid ... Refractory Soli... | Abemaciclib Irinotecan Temozolomide Dinutuximab GM-CSF | - 21 Years | Eli Lilly and Company | |
| Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma | NCT03786783 | Ganglioneurobla... High Risk Neuro... | Autologous Hema... Carboplatin Cisplatin Cyclophosphamid... Dexrazoxane Dinutuximab Doxorubicin Etoposide External Beam R... Isotretinoin Melphalan Sargramostim Thiotepa Topotecan Vincristine | - 30 Years | National Cancer Institute (NCI) | |
| Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma | NCT00026312 | Localized Resec... Localized Unres... Recurrent Neuro... Regional Neurob... Stage 4 Neurobl... Stage 4S Neurob... | Aldesleukin Dinutuximab Isotretinoin Laboratory Biom... Pharmacological... Quality-of-Life... Sargramostim | - 30 Years | National Cancer Institute (NCI) | |
| Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma | NCT01711554 | Recurrent Neuro... Refractory Neur... | Dinutuximab Isotretinoin Laboratory Biom... Lenalidomide Pharmacological... | - 21 Years | National Cancer Institute (NCI) | |
| Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma | NCT02169609 | Neuroblastoma Neoplasm, Resid... Effects of Immu... | Dinutuximab. Im... | - | Fundació Sant Joan de Déu | |
| NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab | NCT04211675 | Relapsed Neurob... Refractory Neur... | Natural Killer ... Temozolomide Irinotecan Dinutuximab Sargramostim | - 29 Years | Nationwide Children's Hospital | |
| Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma | NCT04751383 | High Risk Neuro... Recurrent Neuro... Recurrent Osteo... Refractory Neur... Resectable Oste... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Dinutuximab Magnetic Resona... Magrolimab Resection | 2 Years - 35 Years | National Cancer Institute (NCI) | |
| MIBG With Dinutuximab +/- Vorinostat | NCT03332667 | Neuroblastoma | 131I-MIBG Dinutuximab Vorinostat Sargramostim Potassium Iodid... | 1 Year - 30 Years | New Approaches to Neuroblastoma Therapy Consortium | |
| Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma | NCT01767194 | Ganglioneurobla... Recurrent Neuro... | Dinutuximab Irinotecan Hydr... Laboratory Biom... Sargramostim Temozolomide Temsirolimus | - | National Cancer Institute (NCI) | |
| Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma | NCT01041638 | High Risk Neuro... | Aldesleukin Diagnostic Labo... Dinutuximab Isotretinoin Sargramostim | - | National Cancer Institute (NCI) | |
| Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer | NCT03098030 | Small Cell Lung... | Dinutuximab Irinotecan Topotecan | 18 Years - | United Therapeutics | |
| MIBG With Dinutuximab +/- Vorinostat | NCT03332667 | Neuroblastoma | 131I-MIBG Dinutuximab Vorinostat Sargramostim Potassium Iodid... | 1 Year - 30 Years | New Approaches to Neuroblastoma Therapy Consortium | |
| Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL) | NCT04385277 | Ganglioneurobla... Neuroblastoma | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Dinutuximab FDG-Positron Em... Iobenguane I-12... Irinotecan Isotretinoin Magnetic Resona... Multigated Acqu... Sargramostim Temozolomide | - 30 Years | Children's Oncology Group | |
| Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma | NCT01041638 | High Risk Neuro... | Aldesleukin Diagnostic Labo... Dinutuximab Isotretinoin Sargramostim | - | National Cancer Institute (NCI) | |
| Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma | NCT03794349 | High Risk Neuro... Recurrent Neuro... Refractory Neur... | Dinutuximab Eflornithine Hy... Irinotecan Hydr... Sargramostim Temozolomide | 1 Year - | Children's Oncology Group | |
| Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma | NCT01711554 | Recurrent Neuro... Refractory Neur... | Dinutuximab Isotretinoin Laboratory Biom... Lenalidomide Pharmacological... | - 21 Years | National Cancer Institute (NCI) | |
| NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab | NCT04211675 | Relapsed Neurob... Refractory Neur... | Natural Killer ... Temozolomide Irinotecan Dinutuximab Sargramostim | - 29 Years | Nationwide Children's Hospital | |
| Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma | NCT03794349 | High Risk Neuro... Recurrent Neuro... Refractory Neur... | Dinutuximab Eflornithine Hy... Irinotecan Hydr... Sargramostim Temozolomide | 1 Year - | Children's Oncology Group | |
| Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients | NCT02693171 | Neuroblastoma | Dinutuximab | 1 Year - 18 Years | United Therapeutics |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
